Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast cancer (MBC)

被引：0
|
作者：
Winer, E
Batist, G
Harris, L
Hooftman, L
Park, Y
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Liposome Co, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
59O
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] Clinical studies with evacet (TLC D-99) and doxorubicin (DOX) in patients with metastatic breast carcinoma (MBC)
    Boyle, JA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U237 - U237
  • [2] Phase III study of liposome-encapsulated doxorubicin (TLC D-99) and cyclophosphamide (CPA) vs. epirubicin (EPI) and CPA in first-line treatment of metastatic breast cancer (MBC)
    Chan, S
    Davidson, N
    Juozaityte, E
    Erdkamp, F
    Hooftman, L
    Azarnia, N
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S315 - S315
  • [3] A phase II study of TLC D-99 (liposome encapsulated doxorubicin), in combination with (5-FU) and cyclophosphamide (CPA) in the treatment of metastatic breast cancer (MBC)
    Valero, V
    Azarnia, N
    Buzdar, A
    Theriaulst, R
    Willey, J
    Lee, L
    Hortobagyi, G
    ANNALS OF ONCOLOGY, 1998, 9 : 14 - 14
  • [4] RESPONSE TO LIPOSOME-ENCAPSULATED DOXORUBICIN (TLC D-99) IN A DOG WITH MYELOMA
    KISSEBERTH, WC
    MACEWEN, EG
    HELFAND, SC
    VAIL, DM
    LONDON, CL
    KELLER, E
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 1995, 9 (06): : 425 - 428
  • [5] A phase I study of TLC D-99 (liposome encapsulated doxorubicin) with G-CSF in patients with refractory solid tumours
    Elias, A
    Hooftman, L
    Mazanet, R
    O'Day, S
    Lee, L
    Azarnia, N
    ANNALS OF ONCOLOGY, 1998, 9 : 131 - 132
  • [6] Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer
    Swenson, CE
    Bolcsak, LE
    Batist, G
    Guthrie, TH
    Tkaczuk, KH
    Boxenbaum, H
    Welles, L
    Chow, SC
    Bhamra, R
    Chaikin, P
    ANTI-CANCER DRUGS, 2003, 14 (03) : 239 - 246
  • [7] Liposomal-encapsulated doxorubicin (Myocet™; D-99) and vinorelbine in previously treated metastatic breast cancer patients: a feasibility study
    Poletti, Paola
    Bettini, Anna Cecilia
    Caremoli, Elena Rota
    Labianca, Roberto
    Tondini, Carlo
    TUMORI JOURNAL, 2008, 94 (05): : 686 - 690
  • [8] INITIAL CLINICAL (PHASE-I) TRIAL OF TLC D-99 (DOXORUBICIN ENCAPSULATED IN LIPOSOMES)
    COWENS, JW
    CREAVEN, PJ
    GRECO, WR
    BRENNER, DE
    TUNG, Y
    OSTRO, M
    PILKIEWICZ, F
    GINSBERG, R
    PETRELLI, N
    CANCER RESEARCH, 1993, 53 (12) : 2796 - 2802
  • [9] LIPOSOMAL-ENCAPSULATED DOXORUBICIN (MYOCET; D-99) IN HEAVILY PREVIOUSLY TREATED METASTATIC BREAST CANCER PATIENTS: A FEASIBILITY STUDY
    Giovanardi, Filippo
    Scaltriti, Laura
    Nasuti, Paola
    Artioli, Fabrizio
    ANNALS OF ONCOLOGY, 2009, 20
  • [10] Randomized phase III trials of Myocet (liposome-encapsulated doxorubicin) vs. doxorubicin or epirubicin in first-line treatment of metastatic breast cancer.
    Batist, G
    Winer, E
    Chan, S
    Jain, D
    Lee, L
    Azarnia, N
    ANNALS OF ONCOLOGY, 2000, 11 : 26 - 26
12345